Article
HTA Quarterly Winter 2025 Summary
This edition features the conclusion of our three-part series on France’s Early Access Program (EAP), highlighting the potential of the National Health Database (SNDS) to streamline data collection and offering industry insights on enhancing the program. We also delve into the growing role of multilevel network meta-regression in health technology assessment (HTA), showcasing its ability to address challenges in comparing treatments with limited trial data. Lastly, we summarize findings from a study on leveraging Nordic real-world data to inform PICOs for Joint Clinical Assessments (JCAs), emphasizing the importance of proactive evidence generation and the unique value of Nordic health registries.
Heard on the street
“In a world that feels fragmented, our work can help build bridges. Evidence can be a tool for dialogue and for designing policies that reflect both science and social values.”
– Dr. Andrés Pichon Riviere, Director General of the Institute of Clinical and Health Effectiveness (IECS)
Source: HTAi 2025: the world conference on health technology assessment (IECS) kicked off in Buenos Aires
Source: HTAi 2025: the world conference on health technology assessment (IECS) kicked off in Buenos Aires
HTA by the numbers
9/25
The EMA had estimated that the Member State Coordination Group on Health Technology Assessment (HTACG) would need to conduct 17 JCAs for cancer medicines and 8 JCAs for Advance Therapy Medicinal Products (ATMPs) in 2025; 9 JCAs were underway as of September 2025.
Connect with our team
Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.
